A recent study by Charles River Associates reveals inequities in access to treatment for multiple sclerosis (MS) across Europe. A summary of key findings, with a link to the full report, can be found at the link below.
The end of high drug prices? Exploring the potential and limits of PDABs
Certain states in the US have enacted or are actively considering legislation to create PDABs, Prescription Drug Affordability Boards. PDABs are independent...